A5024020386- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Extracellular vesicles in disease
- Monoclonal and Polyclonal Antibodies Research
- Atherosclerosis and Cardiovascular Diseases
- Systemic Sclerosis and Related Diseases
- Spondyloarthritis Studies and Treatments
- Chronic Lymphocytic Leukemia Research
- Autoimmune Bullous Skin Diseases
- Endometriosis Research and Treatment
- Reproductive System and Pregnancy
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- Angiogenesis and VEGF in Cancer
- Mechanical Circulatory Support Devices
- Whipple's Disease and Interleukins
- Ocular Surface and Contact Lens
- Gout, Hyperuricemia, Uric Acid
- Platelet Disorders and Treatments
- Contact Dermatitis and Allergies
- Inflammasome and immune disorders
- IL-33, ST2, and ILC Pathways
- Blood groups and transfusion
- Autophagy in Disease and Therapy
- Eosinophilic Disorders and Syndromes
Universidade Federal do Rio Grande do Norte
2024
Sapienza University of Rome
2013-2020
Center for Rheumatology
2018
Policlinico Umberto I
2015
Literature data suggest a significantly higher mortality in patients affected by systemic lupus erythematosus (SLE) developing chronic damage. Therefore, damage prevention is major goal the management of SLE patients. In present study, we assessed means Systemic Lupus International Collaborative Clinics/American College Rheumatology (SLICC/ACR) index (SDI), large cohort Additionally, aimed at evaluating its association with demographic and clinical features as well disease activity...
Objective The objective of this paper is to assess the validity a linguistically validated version Lupus Quality Life (LupusQoL © ) in Italian patients affected by systemic lupus erythematosus (SLE). Methods Consecutive SLE completed LupusQoL and Short Form (SF)-36. Disease activity was evaluated disease Index-2000 (SLEDAI-2 K), chronic damage Systemic International Collaborating Clinics/American College Rheumatology (ACR) Damage Index score (SDI). Internal consistency test-retest...
This longitudinal retrospective study aims at describing the safety profile and reasons for discontinuation of antimalarials in patients with systemic lupus erythematosus (SLE) discoid (DLE), focusing on ocular toxicity. We analyzed clinical data 845 SLE DLE patients; 59% them were taking antimalarials: 1.4% chloroquine (CQ), 88.5% hydroxychloroquine (HCQ) 10.1% both. The mean therapy duration was 82.5 ± 77.4 months. At least one side effect reported by 19.4% patients, leading to temporary...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterized by the production of a wide range autoantibodies, resulting from polyclonal B cells activation, impaired apoptotic pathways, or idiotypic network dysregulation. The anti-double stranded DNA antibodies (anti-dsDNA) are considered specific marker for SLE, due to their high frequency, sensitivity and specificity (57.3% 97.4%, respectively). Moreover, identification in other pathological conditions...
Kaposi’s sarcoma (KS) is a low-grade vascular tumor that presents most frequently with skin lesions. Multiple factors are related to KS pathogenesis. The interleukin-23 (IL-23) an immunomodulatory cytokine pro-carcinogenic role. aim of this study was evaluate the detection IL-23 in cutaneous lesions patients classic and KS-AIDS. This cross-sectional conducted at public Hospital Natal, Rio Grande do Norte, Brazil. included 13 biopsies which presented histopathological confirmation. For IL-23,...
<h3>Background</h3> <i>Staphylococcus aureus</i> (SA) is a commensal bacterium which can be isolated mostly in the anterior nares. In immunosuppressive patients, SA could cause various infections, ranging from minor skin infections to severe pneumonia. Data literature reported prevalence of nasal carriage about 25% healthy subjects (HS). Patients affected by Wegener9s granulomatosis and Rheumatoid Arthritis showed significantly higher rates colonisation compared with HS. contrast, there are...
<h3>Background</h3> Vimentin is a cytoskeleton protein of the intermediate filaments family, expressed by mesenchymal cells including vascular endothelial and renal tubular cells. has been recently proposed as target in situ immune response lupus nephritis. Antibodies to vimentin have described 10–53% patients with Systemic Lupus Erythematosus (SLE) account for fibrous pattern cytoplasmic immunofluorescence. Post-translational modifications increase immunogenicity vimentin, demonstrated...
<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease showing a strong predilection for reproductive age women (female/male ratio 9:1). This in part due to the effects exerted by sexual hormones on immune system. The term ovarian reserve has been used traditionally describe number and quality of oocytes women. assessed detection FSH, AMH Estradiol (E2) ultrasonographic (US) evaluation antral follicolar bilateral count (AFC), as recommended Society Reprodutive...
<h3>Background</h3> Circulating endothelial progenitor cells (EPCs) are bone marrow-derived able to differentiate into mature cells; impairment of number and function these is associated with increased subclinical atherosclerosis. Cardiovascular risk highly in patients Systemic Lupus Erythematosus (SLE). Several studies demonstrated that EPCs reduced impaired SLE patients, partially accounting for the dysfunction characterizing patients. In murine models, inhibition B Lymphocyte Stimulator...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE)is a chronic disease requiring long-term treatment. Even though immunosuppresive therapies improved the survival rate,a great percentage of SLE patients exhibit persistently active disease, or flares. Belimumab (BLM), is currently only biological drug approved for treatment not responding to standard care, without kidney neuropsychiatric (NP)involvement. <h3>Objectives</h3> Aim study was analyse 36 months BLM treatment, causes withdrawal...
<h3>Background</h3> There is evidence that autoimmunity, namely RF and ACPA antibodies, may influence disease activities impact the clinical outcomes in RA. <h3>Objectives</h3> <h3>Methods</h3> We analysed longitudinal data of consecutive RA patients from Italian registry GISEA, starting a treatment with golimumab (GOL) tested for rheumatoid factor (RF) anti-citrullinated protein antibodies (ACPA). Demographic related characteristics were collected at baseline, 6 months, 12, 24 months or...
<h3>Background</h3> The role of Toll Like Receptors (TLRs) in Systemic Lupus Erythematosus (SLE) pathogenesis has raised great interest as they recognize nucleic acids, main antigens the disease. Several studies on murine lupus support TLRs onset and progression glomerulonephritis. Data kidney expression humans are scarce; pattern distribution within is controversial not yet been quantified. <h3>Objectives</h3> Aim study was to locate quantify TLR3, TLR7 TLR9 sections SLE patients correlate...
<h3>Background</h3> Lupus nephritis (LN) affects up to 70% of patients with systemic lupus erythematosus (SLE) and is a major cause morbidity mortality. There compelling evidence demonstrating that resident renal cells can directly contribute inflammation through their ability secrete cytokines, chemokines, glycosaminoglycans. Interleukin 32 (IL32) recently described cytokine an important role in both innate adaptive immune responses. IL32 exhibits several properties typical proinflammatory...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a multifactorial autoimmune disease characterized by wide range of clinical manifestations. Fatigue represents frequent symptom reported SLE patients, mainly at the onset, with impact on quality life. The assessment fatigue could be difficult. Functional Assessment Chronic Illness version 4 Therapy (FACIT-F) questionnaire has been validated in chronic diseases to assess adult patients. <h3>Objectives</h3> We aimed assessing fatigue,...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterized by periods of remission and flares. Recently, a monoclonal anti-BLyS (<i>B Lymphocyte Stimulator</i>) antibody, Belimumab, has been approved for the treatment SLE patients with active refractory to conventional therapy. The evaluation Quality Life (QoL) critical issue in global assessment patients, considering possible influence work ability. LupusQoL questionnaire, specifically designed validated....
<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by heterogeneous clinical manifestations and complex pathogenesis. The combination of defective clearance apoptotic cells sustained proinflammatory environment could contribute to the inflammatory state. Circulating, subcellular microparticles (MPs) are released from platelets constitutively upon cellular activation or apoptosis. MPs may reflect state their parental cells, serve as markers...
<h3>Background</h3> Joint involvement is one of the most common manifestations in patients with Systemic Lupus Erythematosus (SLE). The SLE Disease Activity Index 2000 (SLEDAI-2K) identifies presence joint only case ≥2 joints pain and signs inflammation. It therefore clear that this stringent definition could fail to catch great variety expressions involvement. Recently, it has been proposed application Score 28 (DAS28) a cohort ongoing involvement, demonstrating moderate/high disease...
<h3>Background</h3> Cardiovascualar disease is the main comorbidity in Systemic Lupus Erythematosus (SLE). Circulating endothelial progenitor cells (EPCs) are bone marrow-derived cells, able to differentiate into mature cells. Several studies demonstrated a reduction and functional impairment of EPCs SLE patients, contributing dysfunction characterizing these patients. Belimumab (BLM), human monoclonal antibody anti-B Lymphocyte Stimulator (BLyS) first biological drug approved for treatment...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestation and complex pathogenesis. Lymphocytes from patients with SLE display multiple alterations, including increased cell activation, abnormal apoptosis impairment of autophagic pathway. Recently, evidence genetic, biology animal models suggested that autophagy, major pathway for organelle protein turnover, may play pivotal role in the occurrence development...
<h3>Background</h3> The achievement of complete remission is one the most important goal in management patients with Systemic Lupus Erythematosus (SLE). Even though a definition has been proposed (complete absence any clinical and serological sign or symptom activity) concomitant acceptable treatment (including antimalarial drugs only) identified, however minimum lapse time still controversial. This issue primary importance disease characterized by relapsing-remitting course. Several cut-off...
<h3>Background</h3> Microparticles (MPs) are small membrane vesicles released by many cell types under physiological conditions or pathological situations. Increased levels of MPs have been reported in patients with autoimmune diseases, such as Rheumatoid Arthritis (RA) (1) which is characterized an accelerated atherosclerosis. TNF the main cytokine involved pathogenesis RA and studies agree on pro-atherogenic role (2). Furthermore, could a endothelial dysfunction, contributing to...
<h3>Background</h3> Jaccoud arthropathy (JA) is a deforming, non-erosive arthritis, occurringin 2–35% of Systemic Lupus Erythematosus (SLE) patients. The deformities could be easily misdiagnosed as those identified in rheumatoid arthritis (RA), even though, unlike RA, they are reducible. To date no specific markers for JA available. evaluation Rheumatoid Factor (RF) and anti-citrullinated protein antibodies (ACPA) patients demonstrated higher frequency RF comparison with SLE patient without...
<h3>Background</h3> The survival and outcome of patients affected by Systemic Lupus Erythematosus (SLE) have improved dramatically over the past 50 years in terms mortality morbidity rates. However, activity disease long-term therapy could be associated with development a chronic damage <h3>Objectives</h3> To evaluate organ using SLICC/ACR index (SDI) large monocentric well-characterized cohort SLE to investigate its correlation clinical, demographic laboratory features. <h3>Methods</h3>...